Mar 2017

PolyPid Announces Positive Interim Data from Company’s Confirmatory Clinical Trial for BonyPid®-1000 Antibiotic Eluting Bone Substitute

Performance and Safety Endpoints Met for First Patients Having Reached Six-Month Follow-up Period. Petah Tikva, Israel, March 9, 2017 -- PolyPid Ltd., an emerging clinical-stage specialty pharmaceutical company focused primarily on the development of post-surgical anti-infective pipeline, announced today interim results from the first group of patients having reached the six-month follow-up period in the Company's confirmatory…

Read more >
Mar 2017

PolyPid Announces Receipt of Qualified Infectious Disease Product (QIDP) Designation from FDA for D-PLEX™ in Post-Cardiac Surgery Sternal Infection

QIDP Designation Allows for FDA Priority Review and Adds Five Years of Market Exclusivity for  D-PLEX™. D-PLEX™ Currently Subject of On-going Phase Ib/II Study in Israel. Company Intends to Seek Regulatory Approvals in U.S. and Europe in Coming Year to Conduct Phase III Clinical Trial of D-PLEX™. Petah Tikva, Israel, March 08, 2017 -- PolyPid…

Read more >
Feb 2016

PolyPid Announces Completion of $22 Million Series D Financing

Petah Tikva, Israel, February 24, 2016. PolyPid Ltd., an emerging clinical-stage specialty pharmaceutical company,  focused primarily on the development of post-surgical anti-infection pipeline, announced today that it closed a $22 million private equity financing. The financing was co-led by new investor Shavit Capital and current investor Aurum Ventures. The round also included participation of Chaim…

Read more >
Dec 2015

PolyPid Announces First Patient Enrolled in Confirmatory Clinical Trial, Evaluating Performance and Safety of BonyPid-1000™, an Antibiotic Eluting Bone Void Filler

Petah Tikva, Israel, December 2, 2015. PolyPid Ltd., an emerging clinical stage specialty pharmaceutical company, focused primarily on the development of post-surgical anti-infection pipeline, announced today the enrollment of the first patient in the confirmatory clinical trial of BonyPid-1000™, a doxycycline loaded synthetic bone substitute. The BonyPid-1000-103 trial is a randomized, single-blind standard of care controlled…

Read more >
Nov 2015

PolyPid Announces Issuance of New U.S. Patent for Doxycycline Sustained Release Compositions

Petah Tikva, Israel, November 19, 2015. PolyPid, a clinical stage pharmaceutical company and developer of PLEX™, a protected drug reservoir platform for effective localized, controlled and prolonged drug delivery, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,173,976, covering compositions for sustained and/or controlled release of doxycycline.…

Read more >
Jul 2014

PolyPid Announces US Patent Allowance for Sustained Release of Nucleic Acid Matrix Compositions

Petah Tikva, Israel, July 7, 2014. PolyPid, a developer of proprietary medical device and drug delivery solutions, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. application Serial Number 13/574,040, a patent covering compositions for sustained and/or controlled release of nucleic acid agents. A Notice…

Read more >
Jun 2014

PolyPid Wins First Prize at Biomed Startup Competition

Petah Tikva, Israel, June 18, 2014. PolyPid, a developer of proprietary medical device and drug delivery solutions, today announced that it won First Prize in the startup competition at MIXiii Biomed Israel Innovation Conference, held in Tel Aviv.The prize was awarded to PolyPid for the company’s “innovative and prominence solutions that answer a profound need and a…

Read more >

Technology

The PLEX™ (Polymer-Lipid Encapsulation matriX) platform is a matrix made of alternating layers of polymers and lipids that allows controlled, local release of unmodified drugs over extended periods of time.

Read More >

D-PLEX™

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

BonyPid-1000™

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >